Early Lung Cancer Blood Test Completes US Laboratory Validation
The CIZ1B biomarker assay is designed to complement LDCT screening by helping assess lung cancer risk and clarify indeterminate findings.
The CIZ1B biomarker assay is designed to complement LDCT screening by helping assess lung cancer risk and clarify indeterminate findings.
Beckman Coulter Life Sciences has released the Echo 650 Plus Series acoustic liquid handlers, featuring next-generation electronics and a 54% reduction in power consumption for high-throughput labs, according to the company.
Cleveland Diagnostics has received ISO 13485:2016 certification for its IsoPSA Assay, supporting scaled U.S. commercialization following recent FDA approval for prostate cancer risk assessment.
Amplified Sciences has launched the PanAMP multicenter study to assess how its PanCystPro assay impacts clinical management decisions for patients with radiographically confirmed pancreatic cystic lesions.
Read MoreLucent Diagnostics and Tempus AI have partnered to integrate blood-based Alzheimer’s biomarker testing into clinical workflows, aiming to expand access and improve detection accuracy for neurologists.
Read MoreRoche has received CE mark approval for its Elecsys pTau217 blood test, designed to aid in Alzheimer’s disease diagnosis by detecting amyloid pathology in patients with cognitive decline.
Read MoreBio-Rad has expanded its TrailBlazer StarBright Dye Label Kits to 32 options, now available in Europe for flow cytometry and fluorescent western blot applications, according to the company.
Read MoreSynergen Health has introduced IGNITE, an AI-driven revenue cycle management platform for laboratories, aiming to streamline billing and reduce claim denials through automated processes and specialized RCM teams, according to the company.
Read MoreAvant Genomics has secured over $3 million in funding to develop its Avant Source platform, which aims to automate liquid biopsy sample preparation and improve cell-free DNA recovery.
Read MoreLabcorp’s full test menu is now integrated into Epic’s Aura platform, streamlining lab test ordering and results for health systems and reducing IT complexity.
Read MoreNeuroVision Imaging has acquired Durin Life Sciences, combining blood-based biomarker tests with retinal imaging and telehealth to advance early detection of Alzheimer’s and Parkinson’s diseases.
Read MoreFujirebio Europe has received CE marking for its automated Lumipulse G pTau 217 Plasma assay, designed to help identify amyloid pathology in patients with cognitive decline, according to the company.
Read MoreFoundation Medicine and Bristol Myers Squibb have expanded their partnership to develop an NGS-based companion diagnostic for identifying homozygous MTAP deletions, supporting targeted therapy development in precision oncology.
Read MoreThe gastrointestinal molecular diagnostics company’s facility adds College of American Pathologists accreditation to its existing CLIA certification.
Read MorePresentations will feature results from the NHS-Galleri and PATHFINDER 2 studies involving more than 174,000 participants.
Read MoreIllumina will provide clinical sequencing services to Florida State University’s new Diagnostic Lab for Pediatric Rare Diseases, aiming to accelerate rare disease diagnostics for an estimated 30 million affected Americans.
Read MoreInvivoscribe, in collaboration with Hitachi High-Tech, has launched the PrepQuant System, an automated platform that integrates nucleic acid extraction, concentration, and quantification to streamline molecular testing workflows.
Read MoreEarly use of rapid sepsis diagnostics could prevent 36,200 deaths and 84,400 sepsis cases annually in the US, according to a multi-country health economic analysis announced by bioMérieux and conducted by the Office of Health Economics.
Read More